等待开盘 01-30 09:30:00 美东时间
+0.180
+1.02%
今日重点评级关注:HC Wainwright & Co.:维持Soleno Therapeutics"买入"评级,目标价从110美元升至120美元;富国银行:维持Soleno Therapeutics"超配"评级,目标价从106美元升至114美元
01-21 11:42
- Zeleciment basivarsen (z-basivarsen) demonstrated sustained functional improvement across multiple clinical measures in the ongoing ACHIEVE clinical trial -- Expect to complete enrollment in ACHIEVE Registrational
01-20 20:31
Dyne Therapeutics announced the appointment of Vikram Karnani to its Board of Directors. Karnani, a seasoned executive in rare disease and biopharmaceuticals, brings extensive experience in product launches and growth. As Dyne prepares for its first potential launch in Q1 2027, Karnani's expertise aligns with the company's goal of advancing treatments for neuromuscular diseases. His appointment is expected to strengthen Dyne's commercial strategy...
2025-12-23 12:30
今日重点评级关注:HC Wainwright & Co.:维持BioCryst Pharma"买入"评级,目标价从30美元升至32美元;TD Cowen:上调Milestone Pharmaceuticals评级至"买入",目标价8美元
2025-12-16 09:36
Evercore ISI Group analyst Gavin Clark-Gartner maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target from $38 to $36.
2025-12-15 22:54
今日重点评级关注:HC Wainwright & Co.:维持Moleculin Biotech"买入"评级,目标价从4美元升至22美元;HC Wainwright & Co.:上调Soluna Holdings评级至"买入",目标价5美元
2025-12-12 10:24
今日重点评级关注:Ascendiant Capital:维持Lucid Diagnostics"买入"评级,目标价从8美元升至8.25美元;Ascendiant Capital:维持Aytu BioPharma"买入"评级,目标价从12.5美元升至13美元
2025-12-11 10:33
An announcement from Dyne Therapeutics ( ($DYN) ) is now available. On December...
2025-12-11 05:51
Dyne Therapeutics (DYN) priced an upsized underwritten public offering of 18.98M shares at af $18.44 per share. The gross proceeds are expected to be $350.0 million. The offering is expected to close...
2025-12-10 14:39
今日重点评级关注:Chardan Capital:维持Senti Biosciences"买入"评级,目标价从12美元升至13美元;Guggenheim:维持Praxis Precision Medicine"买入"评级,目标价从540美元升至760美元
2025-12-10 10:33